Use of HL-60-related lectins in drug delivery and detection of lectin-expressing cells
US6406679B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Sep 25, 1996 |
| Grant date | Jun 18, 2002 |
| Priority date | — |
| Expiry date | Sep 25, 2016 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/6851
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Pharmaceutical compositions useful in the treatment of autoimmune conditions include as an active ingredient a soluble lectin having a molecular weight of about 14 kilodaltons or a fragment thereof. The lectin or fragment binds &bgr;-galactoside-containing moieties independent of the presence or absence of Ca+2, stimulates hemagglutination of trypsinized rabbit erythrocytes in standard lectin assays wherein the stimulation is inhibited by lactose or thiogalactoside, has an amino acid sequence containing at least one N-glycosylation site and is at least 90% homologous to the amino acid sequence shown in positions 2-135 of FIG. 1 or the relevant portions thereof. The composition is used for treatment of autoimmune conditions such as rheumatoid arthritis, myasthenia gravis, and multiple sclerosis, as well as modulating the immune response in an allergic reactions or to organ or tissue transplant rejection. The inventive composition can be combined with general immunosuppressants.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.